Oracle Alpha Inc. Nurix Therapeutics, Inc. Transaction History
Oracle Alpha Inc.
- $55.7 Billion
- Q1 2024
A detailed history of Oracle Alpha Inc. transactions in Nurix Therapeutics, Inc. stock. As of the latest transaction made, Oracle Alpha Inc. holds 11,538 shares of NRIX stock, worth $223,952. This represents 0.3% of its overall portfolio holdings.
Number of Shares
11,538
Previous 17,434
33.82%
Holding current value
$223,952
Previous $180 Million
5.73%
% of portfolio
0.3%
Previous 0.23%
Shares
2 transactions
Others Institutions Holding NRIX
# of Institutions
144Shares Held
50.3MCall Options Held
30.3KPut Options Held
22.7K-
Black Rock Inc. New York, NY4.58MShares$88.9 Million0.0% of portfolio
-
Redmile Group, LLC San Francisco, CA4.48MShares$87 Million2.6% of portfolio
-
Baker Bros. Advisors LP New York, NY3.88MShares$75.4 Million0.72% of portfolio
-
Deep Track Capital, LP Greenwich, CT3MShares$58.2 Million1.46% of portfolio
-
State Street Corp Boston, MA2.73MShares$53 Million0.0% of portfolio
About Nurix Therapeutics, Inc.
- Ticker NRIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 47,147,800
- Market Cap $915M
- Description
- Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...